| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 03/14/2023 | Acer Therapeutics Inc. | ACER | Grant | Stock Option (right to buy) | 20k | $1.67 | $33.4k | | 03/14/2023 |
| 11/29/2022 | Acer Therapeutics Inc. | ACER | Purchase | Common Stock | 409.8k | $1.22 | $500k | | 11/29/2022 |
| 06/07/2022 | BIOCRYST PHARMACEUTICALS INC | BCRX | Grant | Common Stock | 12.9k | $0.00 | $0 | | 06/07/2022 |
| 06/07/2022 | BIOCRYST PHARMACEUTICALS INC | BCRX | Grant | | 30k | $10.79 | $323.9k | | 06/07/2022 |
| 05/31/2022 | BIOCRYST PHARMACEUTICALS INC | BCRX | Grant | | 569 | $9.31 | $5.3k | | 05/31/2022 |
| 05/11/2022 | Travere Therapeutics, Inc. | RTRX | Sale | Common Stock | 2.6k | $21.92 | $56.5k | | 05/11/2022 |
| 02/28/2022 | BIOCRYST PHARMACEUTICALS INC | BCRX | Grant | | 301 | $16.61 | $5k | | 02/28/2022 |
| 01/14/2022 | Acer Therapeutics Inc. | ACER | Grant | Stock Option (right to buy) | 18.5k | $2.21 | $40.9k | | 01/14/2022 |
| 12/10/2021 | Acer Therapeutics Inc. | ACER | Purchase | Common Stock | 8k | $2.04 | $16.3k | | 12/09/2021 |
| 12/09/2021 | Acer Therapeutics Inc. | ACER | Purchase | Common Stock | 2k | $2.15 | $4.3k | | 12/09/2021 |
| 11/30/2021 | BIOCRYST PHARMACEUTICALS INC | BCRX | Grant | | 414 | $12.06 | $5k | | 11/30/2021 |
| 11/16/2021 | Travere Therapeutics, Inc. | RTRX | Sale | Common Stock | 31.8k | $29.39 | $934.6k | | 11/16/2021 |
| 11/05/2021 | Travere Therapeutics, Inc. | RTRX | Sale | Common Stock | 10k | $26.23 | $262.3k | | 11/05/2021 |
| 11/05/2021 | Travere Therapeutics, Inc. | RTRX | Exercise | Employee stock option (right to buy) | 10k | $16.23 | $162.3k | | 11/05/2021 |
| 11/02/2021 | Travere Therapeutics, Inc. | RTRX | Sale | Common Stock | 3.5k | $30.00 | $105k | See footnote | 11/01/2021 |
| 11/01/2021 | Travere Therapeutics, Inc. | RTRX | Sale | Common Stock | 5k | $29.48 | $147.4k | See footnote | 11/01/2021 |
| 10/07/2021 | Travere Therapeutics, Inc. | RTRX | Sale | Common Stock | 28k | $26.23 | $734.4k | | 10/07/2021 |
| 10/07/2021 | Travere Therapeutics, Inc. | RTRX | Sale | Common Stock | 32k | $26.26 | $840.3k | | 10/07/2021 |
| 10/07/2021 | Travere Therapeutics, Inc. | RTRX | Exercise | Employee stock option (right to buy) | 60k | $16.23 | $973.8k | | 10/07/2021 |
| 08/31/2021 | BIOCRYST PHARMACEUTICALS INC | BCRX | Grant | | 314 | $15.92 | $5k | | 08/31/2021 |
| 07/16/2021 | Travere Therapeutics, Inc. | RTRX | Gift | Common Stock | 3k | $0.00 | $0 | | 11/01/2021 |
| 07/16/2021 | Travere Therapeutics, Inc. | RTRX | Gift | Common Stock | 3k | $0.00 | $0 | See footnote | 11/01/2021 |
| 05/28/2021 | BIOCRYST PHARMACEUTICALS INC | BCRX | Grant | | 634 | $15.77 | $10k | | 05/28/2021 |
| 05/14/2021 | Travere Therapeutics, Inc. | RTRX | Grant | | 3k | $0.00 | $0 | | 05/14/2021 |
| 05/14/2021 | Travere Therapeutics, Inc. | RTRX | Grant | | 9k | $18.27 | $164.4k | | 05/14/2021 |
| 04/16/2021 | Travere Therapeutics, Inc. | RTRX | Sale | Common Stock | 10k | $26.23 | $262.3k | | 04/16/2021 |
| 04/16/2021 | Travere Therapeutics, Inc. | RTRX | Exercise | Employee stock option (right to buy) | 10k | $16.23 | $162.3k | | 04/16/2021 |
| 03/17/2021 | Travere Therapeutics, Inc. | RTRX | Exercise | Employee stock option (right to buy) | 10k | $16.23 | $162.3k | | 03/17/2021 |
| 03/17/2021 | Travere Therapeutics, Inc. | RTRX | Sale | Common Stock | 7.7k | $27.56 | $213k | | 03/17/2021 |
| 03/17/2021 | Travere Therapeutics, Inc. | RTRX | Sale | Common Stock | 10k | $27.35 | $273.5k | | 03/17/2021 |
| 02/26/2021 | BIOCRYST PHARMACEUTICALS INC | BCRX | Grant | | 927 | $10.78 | $10k | | 02/26/2021 |
| 02/21/2021 | Travere Therapeutics, Inc. | RTRX | Exercise | Employee stock option (right to buy) | 25k | $10.09 | $252.2k | | 02/02/2021 |
| 02/04/2021 | Travere Therapeutics, Inc. | RTRX | Gift | Common Stock | 25k | $0.00 | $0 | | 11/01/2021 |
| 02/04/2021 | Travere Therapeutics, Inc. | RTRX | Gift | Common Stock | 25k | $0.00 | $0 | See footnote | 11/01/2021 |
| 02/02/2021 | Travere Therapeutics, Inc. | RTRX | Exercise | Common Stock | 25k | $10.09 | $252.2k | | 02/02/2021 |
|